2011 NBCC Conference Program - National Breast Cancer Coalition

(continued...)BiosWilliam H. Redd, PhD is Vice Chairman of OncologicalSciences and Director of Cancer Prevention andControl at Mount Sinai School of Medicine. A pioneerin the study of psychological and behavioral factorsin cancer, he published the first report on the use ofbehavioral interventions to reduce adverse side effectsof cancer chemotherapy. His current research focuseson cognitive behavioral factors in control of cancerrelatedfatigue and the dissemination of evidencebasedsupportive care interventions to clinicians. Hereceived the 2010 Distinguished Research MentorAward from the Society of Behavioral Medicine and isa member of the DOD Breast Cancer Research ProgramIntegration Panel.Dana Richter, JD is Director of Government Relationsfor the National Breast Cancer Coalition. Prior to hercurrent position, Ms. Richter was a Senior LegislativeAssistant for Representative Frank LoBiondo (NJ-02)with responsibility for issues including health care,the environment and education. She has a Bachelorof Arts degree and a law degree from the University ofAlabama.Alan Rosenblatt, MA, PhD is the Associate Director forOnline Advocacy at the Center for American Progress.He is a frequent speaker and author on digital media,advocacy, and politics, including social networking,blogging, grassroots, and mobile advocacy strategies.Dr. Rosenblatt is the founder of the Internet AdvocacyCenter and the Internet Advocacy Roundtable. He isan adjunct professor at Georgetown, Johns Hopkins,and American Universities, where he teaches Mediaand Politics in the Digital Age, Internet Politics,Digital Political Strategies, and Internet AdvocacyCommunications; is a blogger at the Huffington Post,TechPresident.com and DrDigiPol.com; and a formerfellow at George Washington University's Institute forPolitics, Democracy, & the Internet.Neeraja Sathyamoorthy, PhD received six years ofpostdoctoral training at the University of Wisconsin andbegan working with the National Cancer Institute in1987. Her research experience has been in enzymology,immunology and cancer biology. Dr. Sathyamoorthybecame a Grants Administrator in 1999 as a ProgramDirector in the Tumor Biology & Metastasis Branch at theDivision of Cancer Biology, National Cancer Institute.She is committed to supporting research to betterunderstand the biology of breast cancer and is the NCIProgram Contact for two initiatives: I) Understandingthe Biology of ER-negative breast cancer in racial andethnic groups; and II) Environmental Influences duringWindows of Susceptibility in breast cancer risk.Helen Schiff, MLS became a volunteer at SHARE, a breastand ovarian cancer advocacy and support organizationafter being diagnosed with DCIS in 1989. She is a ProjectLEAD® graduate and a patient representative for the FDA.Last November she represented NBCC at the NCI ConsensusConference on DCIS. Ms. Schiff has reviewed grants for theDepartment of Defense and New York State. Presently,she is the coordinator of SHARE Leaders, a group ofProject LEAD® graduates which meets monthly to discussimportant issues for breast cancer advocacy.Gary Schwitzer has specialized in health care journalismfor 37 years. He is Publisher of HealthNewsReview.org – anaward-winning site that grades health news. He has taughthealth journalism and media ethics at the University ofMinnesota. Gary worked in television news for 15 years – inMilwaukee, Dallas and CNN. He was founding editor-in-chiefof MayoClinic.com. The Kaiser Family Foundation publishedhis 2009 report, The State of U.S. Health Journalism. In 2010the Association of Health Care Journalists published hisCovering Medical Research: A Guide for Reporting on Studies.Steve Shak, MD has served as Chief Medical Officer atGenomic Health since December 2000. From July 1996 toOctober 2000, Dr. Shak served in various roles in MedicalAffairs at Genentech, Inc., most recently as Senior Directorand Staff Clinical Scientist. From November 1989 to July1996, he served as a Director of Discovery Research atGenentech, where he was responsible for PulmonaryResearch, Immunology and Pathology. He led the clinicalteam that gained approval for Herceptin®, a targetedbiologic treatment for breast cancer. He also initiatedthe cancer clinical trials of the anti-angiogenesis agent,anti-VEGF (Avastin®). In addition, Dr. Shak discoveredPulmozyme®, a mucus-dissolving enzyme that is approvedworldwide for the treatment of the genetic disease cysticfibrosis. Prior to joining Genentech, he was an AssistantProfessor of Medicine and Pharmacology at New YorkUniversity School of Medicine.Joy Simha is one of the three Co-Founders of the YoungSurvival Coalition and currently serves on their Board ofDirectors. She represents the YSC on the Board of Directorsof the National Breast Cancer Coalition and serves onthe Executive Committee of NBCC. She was an ad hocreviewer for the Department of Defense Peer ReviewedBreast Cancer Research Program and currently sits on itsIntegration Panel. In 2010, she was appointed to the CDC’sPanel on Breast Cancer in Young Women. She has served asa consumer advocate for various Cochrane CollaborationSystematic Reviews, as a consumer advocate for AHRQ, andas a panel member on the IOM Evidence CommunicationInnovation Collaborative. Her background is in video,media production and writing and she currently resides inNew Jersey with her husband and two children.Dennis Slamon, MD, PhD is Professor of Medicine, Chiefof the Division of Hematology/Oncology and ExecutiveVice Chair for Research within the Dept. of Medicine atUCLA. He is also the Director of Clinical/TranslationalResearch at the Jonsson Comprehensive Cancer Centerand the Director of Revlon/UCLA Women’s CancerResearch Program. Dr. Slamon received his MD fromthe University of Chicago, and his PhD in cell biologyin 1975. Dr. Slamon’s papers have been published innumerous peer-reviewed medical journals. He has beenhonored by many organizations for his contributions toresearch, including by NBCC. He was instrumental in theidentification of the HER2/neu oncogene and the resultingtreatment, trastuzumab (Herceptin®), hailed as the firsttriumph in an emerging wave of targeted therapies. Hiswork continues to impact the breast and ovarian cancerfields with its innovative research.Jean R. Slutsky, PA, MSPH has directed the Center forOutcomes and Evidence (COE), Agency for HealthcareResearch and Quality (AHRQ) at HHS since 2003. Previouslyshe served as acting director of the Center for Practiceand Technology Assessment at AHRQ. Recently, shehas implemented a comparative effectiveness researchprogram that includes evidence synthesis, generation,translation and implementation. Ms. Slutsky oversees theEvidence-based Practice Center program; TechnologyAssessment Program; extramural and intramural researchportfolios for translating research into practice, outcomesand effectiveness research, and cost-effectivenessanalyses; and the National Guideline, Quality Measures,and Quality Tools Clearinghouses. She is a member of theeditorial board of Implementation Science and has servedas project director of the U.S. Preventive Services TaskForce. Ms. Slutsky received her BS at the University of Iowa,an MSPH from the University of North Carolina, and trainedas a Physician Assistant at USC.Chris Stacey is the President of Sapphire Consultingin Washington, DC and has worked in the fundraisingand marketing field for nearly twenty years. Shehas experience in both the non-profit and for-profitsectors including extensive work with corporate andindividual donors, as well as with private foundationsand government. She managed foundation fundraisingfor Children’s Hospital in Washington, DC, helped launchwellness and workplace giving programs, advisedorganizations about board and volunteer development,and trained non-profit staff in fundraising best practices.She is a graduate of Yale University with degrees inEnvironmental Studies and American Studies. She is theVice President of the Sitar Arts Center board, is on theboard of the Palisades Community Fund and is a memberof Leadership Greater Washington and the Associationof Fundraising Professionals.Patricia Steeg, PhD has studied breast cancer metastasisfor 20+ years. She is the author of over 150 scientific paperson the subject. She is a Past President of the MetastasisResearch Society. Dr. Steeg is currently the Chief, Women’sCancers Section, Laboratory of Molecular Pharmacology,NCI. Dr. Steeg discovered the first metastasis suppressorgene and now also works on brain metastasis of breastcancer. Dr. Steeg has been awarded the Brinker Awardfor Basic Research from the Komen Foundation, and isDeputy Editor of the journal Clinical Cancer Research. Sheis a former member and chair of the Integration Panel ofthe DOD BCRP. She is a Core Faculty Member of NBCC’sProject LEAD®.27